Mayne Pharma has agreed to sell its international segment, Mayne Pharma International, to Australian drugmaker Evaris Pharma for $55.5 million in cash. The price is subject to working capital adjustments. The deal values the unit at 0.79 times its FY26 revenue of $70.7 million, and 12.1 times its direct contribution of $4.6 million. The unit includes contract manufacturing and Australian commercial operations, centred on a facility in Salisbury, South Australia. Mayne Pharma will keep its US Women's Health and Dermatology businesses, and will focus entirely on the United States. The company said the proceeds will strengthen its balance sheet and remove the capital needs of an owned factory. The sale needs approval from the Australian Competition and Consumer Commission. Completion is expected in the third quarter of FY27.

Mayne Pharma's profitability fell as it spent on growth. Underlying EBITDA slid 52% in the September quarter as the company invested in women's health and braced for a generic rival in dermatology. about 1 hour ago - 2 mins What's going on here? Mayne Pharma's September-quarter profitability fell fast: underlying EBITDA dropped 52% to AU$5.3 million as the drugmaker spent more to grow women's health and prepared for a new generic rival in dermatology. What does this mean? In a Monday update to the Australian stock exchange, Mayne said September-quarter revenue slipped 2% from a year earlier to AU$95.7 million. But the bigger move was profitability: underlying EBITDA fell from AU$11 million to AU$5.3 million, which the company said reflected planned investment. That spending is aimed at building commercial muscle in women's health, including menopause and contraception products, where growth typically depend... Keep reading for free. This content is free, but you must be logged in to continue reading. Already have an account?

Attorney General Hilgers seeks court approval for settlements with Ascend, Citron and Mayne over conspiracy to inflate prices and limit competition. October 8, 2026 3:05 pm by Karli Ferry 13 total views, 13 views today Suzanne Gage If You Bought Certain Generic Prescription Drugs in the United States Between May 2009 and December 2019, You Could be Eligible for Money. Lincoln-Attorney General Mike Hilgers today joined a coalition of 45 states and territories seeking court approval of three settlements with Ascend Laboratories, Citron Pharma and Mayne Pharma to resolve allegations that the generic drug manufacturers engaged in a widespread, long-running conspiracy to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade with regard to numerous generic prescription drugs. Ascend will pay $400,000 to the states. Mayne will pay $650,000. Citron's settlement only includes non-monetary terms as it has ceased business operations. As part of the settlement, the companies each agreed to meaningful injunctive terms including a series of internal reforms to ensure fair competition and compliance with antitrust laws. These latest settlements come as the States prepare for the first trial to be held in Hartford, Connecticut, in February 2027. The States previously reached settlements with Sandoz, Glenmark, Lannett, Bausch, Apotex, and Heritage, and Heritage's parent company, Emcure, totaling $496.5 million. If you purchased a generic prescription drug between May 2009 and December 2019, you may be eligible for compensation. To determine your eligibility, call 1-866-290-0182 (Toll-Free), email [email protected], or visit www.AGGenericDrugs.com. You can submit a claim for compensation here. Starting in 2016, a coalition of nearly all states and territories engaged in a series of antitrust cases. The first Complaint included Heritage and 17 other corporate Defendants, two individual Defendants, and 15 generic drugs. Two former executives from Heritage Pharmaceuticals, Jeffery Glazer and Jason Malek, have since entered into settlement agreements and are cooperating. The second Complaint was filed in 2019 against Teva Pharmaceuticals and 21 of the nation's largest generic drug manufacturers. The Complaint names 16 individual senior executive Defendants. The third complaint, to be tried first, focuses on 80 topical generic drugs that account for billions of dollars of sales in the United States and names 26 corporate defendants and 10 individual defendants. The States filed a fourth complaint earlier this year, alleging that Novartis AG, Sandoz Group AG and Sandoz AG, are liable for Sandoz's alleged conduct and for fraudulently transferring assets. The cases all stem from a series of investigations built on evidence from several cooperating witnesses at the core of the different conspiracies, a massive document database of over 20 million documents, and a phone records database containing millions of call detail records and contact information for over 600 sales and pricing individuals in the generics industry. Each complaint addresses a different set of drugs and defendants, and lays out an interconnected web of competing industry executives that met with each other during industry dinners, "girls' nights out," lunches, cocktail parties, golf outings, and communicated via frequent telephone calls, emails, and text messages that sowed the seeds for their illegal agreements. Throughout the complaints, defendants use terms like "fair share," "playing nice in the sandbox," and "responsible competitor" to describe how they unlawfully discouraged competition, raised prices, and enforced an ingrained culture of collusion. Among the records obtained by the States is a two-volume notebook containing the contemporaneous notes of one of the States' cooperators that memorialized his discussions during phone calls with competitors and internal company meetings over a period of several years. States and territories joining the settlements include: Alaska, Arizona, California, Colorado, Connecticut, Delaware, the District of Columbia, Florida, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.